## Drug Summary
4-Hydroxytamoxifen is an active metabolite of the widely used estrogen receptor modulator, tamoxifen. It belongs to the class of drugs known as selective estrogen receptor modulators (SERMs). Tamoxifen itself is extensively used in the treatment and prevention of breast cancer, particularly in hormone receptor-positive breast cancer. The effectiveness of tamoxifen is greatly attributed to its metabolism into 4-hydroxytamoxifen, which is considered to be significantly more potent at binding the estrogen receptor (ER) than tamoxifen. This binding leads to inhibition of estrogen-mediated transcriptional activity, reducing the growth and proliferation of breast cancer cells. 

## Drug Targets, Enzymes, Transporters, and Carriers
Since the provided DrugBank information was empty, I'll rely on common pharmacological literature. The primary mechanism of action of 4-hydroxytamoxifen is the competitive inhibition of the estrogen receptor. By binding to the estrogen receptor, 4-hydroxytamoxifen prevents estrogen from interacting with the receptor, inhibiting the receptor's transcriptional activity which is vital for tumor growth in hormone-sensitive breast cancer pathways. There is also evidence suggesting the involvement of other molecular pathways and potential apoptotic effects on cancer cells, contributing to its therapeutic benefits.

## Pharmacogenetics
The pharmacogenetics of 4-hydroxytamoxifen is influenced significantly by the genetic variability in the cytochrome P450 enzymes, mainly CYP2D6, which is crucial for the bioactivation of tamoxifen to 4-hydroxytamoxifen. Genetic polymorphisms in CYP2D6 can significantly affect the concentrations of 4-hydroxytamoxifen and thus its therapeutic efficacy. Patients with reduced function or non-functional alleles of CYP2D6 may exhibit poor metabolic conversion of tamoxifen to 4-hydroxytamoxifen, leading to suboptimal drug response. Therefore, genotype-based dosing may be considered. Moreover, studies have also highlighted the importance of other genes like SULT1A1 and UGT2B15, which are involved in the further metabolism and disposition of the drug. The genetic variations in these pathways might contribute to differences in drug efficacy and safety profiles between individuals.